Sareum Collaborates with Almirall Prodesfarma
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Sareum Holdings plc has announced that it has entered into a collaborative agreement with Almirall Prodesfarma S.A., to provide protein structure determination capabilities to accelerate drug discovery research at Almirall.
Sareum will utilise its skills in high throughput protein expression, purification and structure determination with the aim of illustrating the precise nature of how Almirall's potential drug candidates interact with their target proteins.
This information will assist Almirall's scientists in their design of new and improved therapeutics against inflammatory diseases.
Sareum's Chief Executive Officer, Dr Tim Mitchell, said: "We are delighted that Almirall has chosen Sareum as their partner in protein structure determination."
He adds, "This is a further important collaboration that Sareum has signed since we started trading on AIM. We look forward to successful delivery of this project to Almirall and to closing additional partnerships such as this."
Almiralls's General Director for Research & Development, Dr José M Palacios, said: "We consider protein structure determination as an essential element in a modern drug discovery strategy, and we have high expectations that this collaboration with Sareum will allow Almirall to significantly leverage its drug discovery capacity."
Sareum will utilise its skills in high throughput protein expression, purification and structure determination with the aim of illustrating the precise nature of how Almirall's potential drug candidates interact with their target proteins.
This information will assist Almirall's scientists in their design of new and improved therapeutics against inflammatory diseases.
Sareum's Chief Executive Officer, Dr Tim Mitchell, said: "We are delighted that Almirall has chosen Sareum as their partner in protein structure determination."
He adds, "This is a further important collaboration that Sareum has signed since we started trading on AIM. We look forward to successful delivery of this project to Almirall and to closing additional partnerships such as this."
Almiralls's General Director for Research & Development, Dr José M Palacios, said: "We consider protein structure determination as an essential element in a modern drug discovery strategy, and we have high expectations that this collaboration with Sareum will allow Almirall to significantly leverage its drug discovery capacity."
